Trevena (TRVN) Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Trevena in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TRVN shares.
View TRVN analyst ratings or view top-rated stocks.

2 analysts have issued twelve-month target prices for Trevena's shares. Their TRVN share price forecasts range from $2.00 to $9.00. On average, they anticipate the company's stock price to reach $5.50 in the next year. This suggests a possible upside of 708.9% from the stock's current price.
View analysts price targets for TRVN or view top-rated stocks among Wall Street analysts.

Trevena's stock was trading at $1.43 at the start of the year. Since then, TRVN shares have decreased by 52.5% and is now trading at $0.6799.
View the best growth stocks for 2023 here.

Trevena saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 1,130,000 shares, an increase of 207.5% from the August 31st total of 367,500 shares. Based on an average daily trading volume, of 615,800 shares, the short-interest ratio is presently 1.8 days. Approximately 8.4% of the company's shares are short sold.
View Trevena's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our TRVN earnings forecast.

Trevena, Inc. (NASDAQ:TRVN) announced its quarterly earnings data on Monday, August, 14th. The biopharmaceutical company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.45) by $0.24. The biopharmaceutical company earned $3.02 million during the quarter, compared to analysts' expectations of $0.70 million.

Shares of Trevena reverse split on Wednesday, November 9th 2022. The 1-25 reverse split was announced on Wednesday, November 9th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, November 9th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Trevena investors own include Conatus Pharmaceuticals (CNAT), Novavax (NVAX), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), SCYNEXIS (SCYX), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Aeterna Zentaris (AEZS), Bionano Genomics (BNGO) and Dynavax Technologies (DVAX).

Trevena trades on the NASDAQ under the ticker symbol "TRVN."

Trevena's stock is owned by many different institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (1.66%) and Citadel Advisors LLC (0.00%). Insiders that own company stock include Barry Shin and Carrie L Bourdow.
View institutional ownership trends.

Shares of TRVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TRVN stock can currently be purchased for approximately $0.68.

Trevena (NASDAQ:TRVN) has a market capitalization of $9.32 million and generates $2.59 million in revenue each year. The biopharmaceutical company earns $-53,670,000.00 in net income (profit) each year or ($4.48) on an earnings per share basis.

Trevena's mailing address is 955 Chesterbrook Boulevard Suite 110, Chesterbrook PA, 19087. The official website for the company is www.trevena.com. The biopharmaceutical company can be reached via phone at (610) 354-8840 or via email at ir@trevena.com.